Correction. In the article "Coordinate tropic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain-cleavage enzyme, P450ssc, in human steroidogenic tissues" by Raimo Voutilainen and Walter L. Miller, which appeared in number 6, March 1987, of Proc. Natl. Acad. Sci. USA (84,(1590)(1591)(1592)(1593)(1594), an editorial error should be noted. In the third line of the title and 21st line of the abstract, P450scc was mistakenly set as P450ssc. The correct title is:
fetal adrenal cells, ACTH and dibutyryl cAMP increased IGF-ll mRNA accumulation, but human chorionic gonadotropin and angiotensin II did not. The same five size species of IGF-II mRNA were detected in transfer blots of RNA from granulosa cells and fetal adrenal cells, and all ofthese increased after hormonal stimuli. Dibutyryl cAMP also increased IGF-II mRNA accumulation in cultured human placental cells. Accumulation of mRNA for the cholesterol side-chain-cleavage monooxygenase [P450ssc; cholesterol,reduced-adrenal-ferredoxin:oxygen oxidoreductase (side-chain-cleaving), EC 1.14.15.6] was regulated in parallel with IGF-ll mRNA in all these steroidogenic tissues. IGF-I mRNA was not detected in transfer blots of these RNAs, and the minimal amounts detected in dot blots showed no detectable change after any of the hormonal stimuli studied. The data indicate that the IGF-ll gene is expressed in human steroidogenic tissues and is regulated by cAMP. These data suggest that IGF-H may act in an autocrine or paracrine fashion to stimulate the adrenal and gonadal growth stimulated by ACTH and gonadotropins, respectively.
Insulin-like growth factor type I (IGF-I) is a 70-amino acid polypeptide mediating some of the somatotrophic effects of growth hormone. The classical "somatomedin hypothesis," wherein IGF-I is produced in the liver and secreted as a hormone in response to pituitary growth hormone (1) , has been verified and expanded. Recent studies have shown that immunoreactive IGF-I is present in many tissues in concentrations too high to be explained by blood-borne hepatic IGF-I (2, 3), and IGF-I mRNA has been detected in a broad variety of tissues (4) (5) (6) . Thus, locally produced IGF-I may have important autocrine or paracrine functions in addition to its endocrine somatotrophic action (2, 7).
Insulin-like growth factor type II (IGF-II) is a 67-amino acid polypeptide structurally related to IGF-I. IGF-II is probably produced in several tissues (6, 8) , but its function and regulation of production are poorly understood. Growth hormone does not appear to stimulate IGF-II secretion significantly, as serum concentrations are not elevated in acromegaly, although they are somewhat decreased in growth hormone deficiency (9) . IGF-II may be a fetal growth factor (8, (10) (11) (12) , and it may have a role in the genesis of Wilms tumor, a fetal neoplasm (8, 13) . The human IGF-II gene is closely linked to the insulin genes on chromosome 11, while the IGF-I gene is on chromosome 12 (14) (15) (16) .
The cleavage of the cholesterol side chain to yield pregnenolone is the first, rate-limiting, and hormonally regulated step in steroid-hormone synthesis. This reaction is catalyzed by a single mitochondrial cholesterol side-chain-cleavage monooxygenase [P450scc; cholesterol,reduced-adrenal-ferredoxin:oxygen oxidoreductase (side-chain-cleaving), EC 1.14.15.6] (17, 18) . The single human P450scc gene lies on chromosome 15 and is transcribed into identical mRNAs in the adrenal and gonad (19, 20) . It is primarily regulated by corticotropin [adrenocorticotropic hormone (ACTH)] and gonadotropins, respectively, acting via cAMP (17, 18, (21) (22) (23) .
IGFs stimulate granulosa cell growth and steroidogenesis. IGF-I induces proliferation of bovine granulosa cells (24) . IGF-I and IGF-II increase thymidine incorporation and facilitate progesterone secretion in porcine granulosa cell cultures (25, 26) . IGF-I induces synthesis of P450scc and adrenodoxin in cultured swine granulosa cells (27) . IGF-I also enhances follicle-stimulating hormone (FSH)-induced aromatase activity (28) , progesterone synthesis (29) , and luteinizing hormone receptors (30) in cultured rat granulosa cells. In addition, porcine granulosa cells may produce and secrete IGFs into culture medium and follicular fluid (31) .
Growth hormone may stimulate IGF-I synthesis in the rat ovary (32) , but the control of synthesis of IGF-I and IGF-II in human steroidogenic tissues is unknown. We show that human growth hormone had no effect on IGF-I or IGF-II mRNA in human ovarian granulosa cells. Furthermore removed on a Ficoll-Paque gradient as described (22) . Cells (5 x 105) were plated on 6-cm plastic culture dishes in the medium described above. The medium was changed 2 days after plating, and the experiments were begun at that time so that the hormonal stimuli were from day 2 to day 4 of culture. Hormones were as described (22) .
RNA Analysis. Cells were harvested, and cytoplasmic RNA was prepared and analyzed by dot blots as described (22) , except that Nytran nylon membranes (Schleicher & Schuell) were substituted for nitrocellulose and the hybridization buffer contained 0.1% NaDodSO4. RNA was quantified by absorption at 260 nm; ratios of absorption at 260 vs. 280 nm and at 260 vs. 230 nm were always >1.75. All samples for each series of experiments were on single filters. All blots were probed with human actin cDNA (33) to verify that equivalent amounts of mRNA were loaded; actin mRNA did not vary significantly in any experiment. RNA transfer blots and statistical analyses were also performed as described (22) .
Probes. Our full-length human P450scc cDNA has been described (20) . Human IGF-I and IGF-II cDNA plasmids phigf 1 and phigf 2 (34) were provided by Leslie Rall and Graeme Bell (Chiron Corp., Emeryville, CA). Human IGF-I and II cDNA plasmids (35) were also provided by Peter Rotwein (Washington Univ., St. Louis, MO). Cloned inserts were cleaved from plasmid vector DNA, separated and electroeluted from agarose gel, and labeled to >108 cpm/,g by nick-translation. RESULTS IGF-ll and P450scc mRNAs in Cultured Granulosa Cells. The abundances of both IGF-II and P450scc mRNAs varied as a function of age of the granulosa cell cultures. Without hormonal stimulation, IGF-II mRNA was most abundant at 3 to 6 days of culture and decreased thereafter (Fig. 1) . Stimulation with FSH resulted in a small increase over control, with a maximum at 6-12 days. However, the responsiveness of IGF-II mRNA to hormonal stimulation with human chorionic gonadotropin (hCG) or Bt2-cAMP reached a maximum at 12-18 days of culture. In the unstimulated basal state, P450scc mRNA was greatest at 3 days, but its responsiveness to hCG and Bt2-cAMP compared to control values was also greatest at 12 days (Fig. 2) Dose-Response of Cultured Granulosa Cells to Hormonal Stimuli. Cultured human granulosa cells accumulate mRNAs for IGF-II and P450scc in a dose-response fashion to hormonal stimuli. In response to hCG, IGF-II mRNA increases to 800% of control (P < 0.001), and P450scc mRNA increases to 620% of control (P < 0.001) (Fig. 3) . FSH stimulates accumulation of IGF-II mRNA to a similar extent (1000%; P < 0.001) but is a less effective stimulator of P450scc mRNA accumulation (300% of control; P < 0.001) (Fig. 4) . Bt2-cAMP stimulates IGF-II mRNA accumulation to 950% (P < 0.001), an extent equivalent to that of hCG or FSH, and stimulates P450scc mRNA accumulation to 590% (P < 0.001), an extent similar to that seen with hCG (Fig. 5) (Tables 1 and 2 ). Furthermore, coincubation of cultures with 100 ng of prolactin or 100 ng of growth hormone per ml for 2 days did not alter the responses of IGF-II and P450scc mRNAs to stimulation with 100 ng of hCG per ml (not shown).
Hormonal Stimulation of IGF-II mRNA in Other Steroidogenic Tissues. Cultured human fetal adrenal and placental cells also accumulated IGF-II mRNA in response to agents stimulating P450scc mRNA. Primary cultures of human fetal adrenal cells were grown 8 days without hormonal stimuli and then 0.1-1 ,uM ACTH or 1 mM Bt2-cAMP was added for 2 days. Blot-hybridization analysis of RNA from these cells showed five size species of IGF-II mRNA of about 4.9, 4.0, 2.7, 2.0 and 1.65 kilobases (kb) (Fig. 6 ). These five species were found in about the same relative abundance in RNA from fetal adrenal cells stimulated with ACTH or cAMP and in RNA from granulosa cells treated with gonadotropins or cAMP. The relative abundance of the five size species of IGF-II mRNA was different, however, in cultured human fibroblasts (Fig. 6 ). Probing similar blots with P450scc cDNA showed a single band of about 2.0 kb in all experiments (20, 22, 23, 36) . P45Oscc mRNA also increased in response to ACTH and Bt2-cAMP, but angiotensin II and hCG did not increase either IGF-II or P450scc mRNAs in cultured human fetal adrenal cells (Table 3) .
In primary cultures of midterm human placental cells, Bt2-cAMP stimulated accumulation of mRNAs for both IGF-II and P450scc (Table 4) . Growth hormone (100 ng/ml) and hCG (100 ng/ml) had no detectable effect on either IGF-II or P450scc mRNA in these cells.
IGF-I mRNA in Steroidogenic Tissues. IGF-I mRNA was barely detectable in granulosa cell RNA and did not increase in response to hormonal stimuli. Before the RNA blots in Fig. A 6 were probed with IGF-II cDNA, they were probed with IGF-I cDNA labeled to the same specific activity as the IGF-II probe. Although a 3-week autoradiographic exposure revealed no detectable bands of IGF-I mRNA, only an overnight exposure was needed to produce the IGF-II mRNA signal seen in Fig. 6 . Therefore, if IGF-I mRNA is present in these cells, it must be at exquisitely low concentrations compared to IGF-II and P450scc mRNAs. Similar 3-week exposures of dot blots probed with IGF-I cDNA showed a slight, consistent signal in dots of granulosa cell RNA, a greater signal in rhesus monkey liver and rat adrenal, and a minimal signal from porcine testis (Table 1) ; no signal was detected in rat pituitary tumor cells or yeast cells. These observations suggest that human granulosa cells do contain small amounts of IGF-I mRNA. Probing of the dot blots (Table 2) . Such high concentrations of progesterone stimulated by large doses of hCG (22) might account for the apparent inhibitory effect of hCG at 100 ,tg/ml on IGF-II mRNA (Fig. 3 ). This might also account for the somewhat lower values for IGF-II mRNA in 3-day-old cultures treated with hCG, compared to controls. The mRNAs for IGF-II and P450scc also accumulate in roughly equivalent proportions. In granulosa cells both (7, (25) (26) (27) (28) (29) (30) . Immunoreactive IGF-I is increased in whole ovarian extracts of rats treated with diethylstilbestrol and ovine growth hormone, suggesting local, growth-hormone-dependent produption of IGF-I in rat ovaries, but the cellular site of this IGF-I synthesis was not examined (32) . Human growth hormone did not increase IGF-I mRNA (or IGF-II and P450scc mRNAs) in human granulosa cells; this may indicate that the site of ovarian IGF-I production is not the granulosa cell, or it may indicate a species difference between the rat and human ovary. By contrast, the huge amounts of IGF-II mRNA in human steroidogenic tissues suggest IGF-II may function locally in an autocrine or paracrine fashion. This is consistent with the recent demonstration that more IGF-II than IGF-I is synthesized and secreted by cultured human placental explants (37) .
The role of this IGF-II remains unknown; however, we suggest that it mediates local growth of steroidogenic tissues in response to pituitary tropic hormones. Although the actions of ACTH or gonadotropins to stimulate hypertrophy and hyperplasia of the adrenals and gonads, respectively, are well known, it has never been clear why agents stimulating the conversion of cholesterol to pregnenolone should also stimulate organ growth. The simultaneous, tissue-specific hormonal stimulation of a locally acting growth factor such as IGFII may explain this. IGF-II may be a locally acting growth factor in many organs including brain (38) and kidney (8, 13) . It will be of great interest to examine the role of IGF-II in other systems of tissue-specific growth such as hormonemediated hypertrophy of other endocrine organs or the compensatory hypertrophy of liver, kidney, and other tissues following surgical reduction of their mass.
